The first 29 amino acids of growth hormone-releasing hormone — a synthetic analog that preserves your natural GH pulsatile rhythm instead of replacing it. Here's what the published research actually shows.
Sermorelin is a truncated analog of endogenous GHRH, containing the first 29 of the 44 amino acids — the biologically active fragment. It binds to GHRH receptors (GHRH-R) on somatotroph cells in the anterior pituitary gland.
Sermorelin (GRF 1-29 NH₂) retains full biological activity of native 44-amino-acid GHRH. The first 29 residues contain the complete receptor-binding domain necessary for pituitary stimulation.
Binds specifically to GHRH receptors on anterior pituitary somatotrophs. This triggers intracellular cAMP signaling, opening calcium channels and stimulating GH vesicle release — the same pathway used by endogenous GHRH.
Unlike exogenous HGH, sermorelin's effects are governed by somatostatin negative feedback. The hypothalamus can still "turn off" GH release — making overdose of endogenous GH difficult or impossible (Walker 2006, PMC2699646).
Stimulates pituitary gene transcription of hGH messenger RNA, increasing pituitary reserve over time. This helps preserve the GH neuroendocrine axis — the first hormonal axis to fail during aging (Walker et al. 1994).
Plasma half-life of approximately 10–20 minutes. Rapid clearance means it creates a GH pulse rather than sustained elevation — mimicking the body's natural secretory pattern.
Only works if the pituitary retains functional somatotrophs. In true pituitary failure, sermorelin is ineffective — this is why it was used as a diagnostic test for GH deficiency in children (PMID: 18031173).
Growth hormone is secreted in episodic pulses, not at a constant rate. This pulsatile pattern is critical for receptor sensitivity and downstream signaling. Sermorelin preserves this rhythm; exogenous HGH does not.
Episodic pulses with somatostatin-regulated troughs. Receptor sensitivity maintained. Mirrors natural physiology.
"Square wave" pharmacological presentation. Prolonged supraphysiological levels. Can lead to tachyphylaxis and reduced efficacy over time.
Key difference: Sermorelin creates GH pulses regulated by somatostatin feedback. Exogenous HGH bypasses the pituitary entirely — the body cannot modulate tissue exposure. As Walker (2006) notes: "Because sermorelin increases endogenous hGH by stimulating the pituitary gland, tachyphylaxis is avoided because sermorelin-induced release of pituitary hGH is not 'square wave', but instead simulates more normal physiology."
Approximately 70% of daily GH secretion occurs during slow-wave (deep) sleep. GHRH administration has been studied for its effects on sleep architecture and nocturnal GH output.
The largest GH pulse occurs within the first 90 minutes of sleep onset, during Stage 3/4 slow-wave sleep. Sermorelin administered before bed amplifies this natural peak rather than creating an artificial one.
Nightly GHRH analog administration at 2100h induced acute GH release within 10 minutes, lasting ~2 hours. Significant increase in 12-hour integrated nocturnal GH in both women (P<0.01) and men (P<0.05) (PMID: 9141536).
GHRH and slow-wave sleep share a bidirectional relationship. GHRH promotes non-REM sleep via hypothalamic pathways. Exogenous GHRH increases slow-wave sleep duration in aging adults (Steiger et al., PMID: 1448189).
Honest note on sleep data: The Khorram 1997 trial assessed sleep quality via self-administered questionnaires and found it was unaffected in both genders. The sleep benefits commonly reported in clinical practice may reflect individual variation, GH-mediated recovery improvements, or a different assessment methodology than subjective questionnaires. Broader GHRH literature (Steiger 1992) does show slow-wave sleep enhancement.
GH stimulates hepatic production of IGF-1 (insulin-like growth factor 1), the primary mediator of GH's anabolic and metabolic effects. The Khorram 1997 trial tracked multiple biomarkers over 16 weeks.
Serum IGF-1 rose within 2 weeks of starting GHRH analog treatment. IGFBP-3 (the main IGF-1 binding protein) increased significantly (P<0.001), indicating genuine somatotropic axis activation, not just lab noise.
Lean body mass increased in men (P<0.05) but not women over 16 weeks. Skin thickness improved in both genders. No significant changes in bone mineral density were observed in this timeframe.
Fasting insulin and glucose levels were unaltered. Men showed improved insulin sensitivity (P<0.05). General well-being (P<0.05) and libido (P<0.01) improved in men but not women — suggesting gender-dependent responses.
Gender differences: The Khorram study found notably different responses between men and women. Men showed improvements in lean body mass, insulin sensitivity, well-being, and libido. Women showed increased skin thickness and IGF-1/IGFBP-3 rises but fewer symptomatic improvements. The authors noted further study was needed to define these gender differences.
The fundamental difference: sermorelin tells your pituitary to make more GH. Exogenous HGH replaces your pituitary's output entirely. This distinction has cascading implications for safety, cost, and physiology.
Legal note: The Code of Federal Regulations specifically restricts the use of recombinant HGH in adults to treatment of AIDS wasting or diagnosed GHD (21 USC §333(e)). Sermorelin, as a GHRH analog rather than HGH itself, does not carry these same federal restrictions and can be prescribed off-label (Walker 2006, PMC2699646).
Multiple peptides stimulate GH release through different receptors and mechanisms. Here's how they compare.
| Property | Sermorelin | Ipamorelin | CJC-1295 (DAC) | Tesamorelin |
|---|---|---|---|---|
| Type | GHRH analog (1-29) | Ghrelin mimetic (GHRP) | GHRH analog (modified) | GHRH analog (1-44) |
| Receptor Target | GHRH-R (pituitary) | GHS-R / Ghrelin receptor | GHRH-R (pituitary) | GHRH-R (pituitary) |
| Half-Life | ~10–20 min | ~2 hours | ~6–8 days (DAC version) | ~26 min |
| GH Release Pattern | Acute pulse | Acute pulse | Sustained elevation | Acute pulse |
| Cortisol Effect | Minimal | Minimal (selective) | Minimal | Minimal |
| Prolactin Effect | Small acute rise | No significant effect | No significant effect | Minimal |
| FDA History | Approved 1997 (Geref), discontinued 2008 | Not FDA-approved | Not FDA-approved | FDA-approved (Egrifta) for HIV lipodystrophy |
| Best For | General GH restoration, sleep, anti-aging | Clean GH pulse, recovery, minimal sides | Sustained IGF-1, less frequent dosing | Visceral fat reduction (FDA-indicated) |
| Typical Dose | 200–300 mcg SC daily | 200–300 mcg SC daily | 1–2 mg SC weekly (DAC) | 2 mg SC daily |
| Common Combo | + Ipamorelin | + CJC-1295 or Sermorelin | + Ipamorelin | Standalone |
Synergistic pairing: Sermorelin (GHRH-R agonist) and ipamorelin (GHS-R agonist) act on different receptors and can produce a synergistic GH pulse greater than either alone. This "GHRH + GHRP" combination is one of the most common protocols in clinical practice. CJC-1295 without DAC (Mod GRF 1-29) is a modified sermorelin with extended half-life (~30 min) and is often used interchangeably in combination protocols.
Standard clinical dosing based on published literature and clinical practice guidelines. Sermorelin is typically supplied as a lyophilized powder requiring reconstitution with bacteriostatic water.
200–300 mcg subcutaneous injection
Lyophilized powder reconstituted with bacteriostatic water (0.9% benzyl alcohol).
Subcutaneous injection using insulin syringes.
Important context from published data:
Based on published clinical data (Khorram 1997) and clinical practice observations. Individual responses vary significantly based on age, baseline GH status, and pituitary function.
IGF-1 plateau note: In the Khorram trial, IGF-1 and IGFBP-3 levels rose significantly within 2 weeks but returned toward baseline by 16 weeks in both genders. This suggests either tachyphylaxis at the dose used (10 mcg/kg) or physiological adaptation. The GH-releasing effect of the GHRH analog itself was sustained throughout the study — the attenuation was in downstream markers.
Sermorelin has a well-documented safety profile from its years as an FDA-approved product (Geref) and subsequent clinical use. Side effects are generally mild and localized.
Because sermorelin works through the GHRH receptor, somatostatin can still shut down GH release. This makes GH overdose from sermorelin extremely unlikely — a key safety advantage over exogenous HGH.
Geref was discontinued by EMD Serono in 2008 for commercial reasons, NOT safety or efficacy concerns. The FDA explicitly confirmed this in a 2013 Federal Register notice (78 FR 14093).
The only adverse side effect in the 16-week trial was transient hyperlipidemia that resolved by study end. Blood pressure, body weight, and fasting glucose were unaffected. No serious adverse events reported (PMID: 9141536).
All data on this page is sourced from peer-reviewed published research. Primary sources cited:
Third-party tested compounds from Swiss Chems — one of the most trusted research suppliers.
Affiliate link — supports MeetPeptide at no extra cost. All Swiss Chems products include third-party lab testing certificates.
Essential supplies for peptide preparation and administration.
Affiliate links help support MeetPeptide at no extra cost to you.
More MeetPeptide research pages related to growth hormone, peptides, and protocols.
Disclaimer: This page is for educational and informational purposes only. It is not medical advice. Sermorelin was previously FDA-approved (Geref, 1997–2008) for pediatric growth hormone deficiency; the branded product was discontinued for commercial reasons. It is currently available only as a compounded medication, which is not individually FDA-approved. Always consult with a qualified healthcare provider before starting any medication or peptide protocol.
Data sourced from published peer-reviewed research. All PubMed IDs and DOIs are linked for independent verification.
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.